Full-Time

Formulation Development Manager

Analytics

Updated on 5/26/2026

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

Compensation Overview

£47k - £53k/yr

Cambridge, UK

In Person

Category
Biology & Biotech (1)
Requirements
  • PhD in a life science discipline (e.g. Biochemistry, Chemistry, Pharmaceutical Sciences) or equivalent relevant experience
  • Significant industrial experience in protein formulation development and/or protein analytical characterisation
  • Demonstrated experience planning and leading scientific projects in a client-facing or commercial environment
  • Experience supervising, coaching, or mentoring scientists, or clear readiness to step into a people management role
  • Strong understanding of analytical techniques relevant to biotherapeutic development, such as SE-HPLC, IEX, CE-SDS, and icIEF
  • Excellent written and verbal communication skills, with the ability to review high-quality reports and present complex data clearly
  • Strong organisational skills, attention to detail, and a proactive, problem-solving approach
Responsibilities
  • Lead and manage formulation development projects or multiple concurrent studies, ensuring high scientific standards, robust data generation, and on-time delivery
  • Design, plan, and oversee routine and complex formulation and analytical studies, including the development or application of novel or specialised techniques where required
  • Critically analyse, interpret, and review experimental data generated by yourself and other team members
  • Take ownership of client deliverables, including study plans, data packages, technical reports, and presentations
  • Actively participate in client meetings, contributing scientific insight, recommendations, and clear communication of results
  • Contribute to cross-group projects by working collaboratively with colleagues across Analytics and other departments
  • Manage your own workload and oversee the work schedules and priorities of junior scientists and direct reports
  • Provide scientific supervision of complex work, offering guidance and constructive feedback to maintain high standards of quality and compliance
  • Review laboratory notebooks, data, and reports produced by team members
  • Coach and mentor scientists to support their technical development, problem-solving skills, and professional growth
  • Contribute to performance management activities, including objective setting, feedback, and development discussions
  • Author and/or review Quality and Controlled documents in line with internal systems and regulatory expectations
  • Contribute to the development of new technologies, methodologies, or service offerings within formulation development
  • Identify areas of research, innovation, or capability improvement that could enhance service provision
  • Act as a project lead or champion for technology development initiatives, working with colleagues and Business Development to support commercialisation
  • Provide technical input into proposals, standard study designs, and work plans
  • Identify potential equipment or capability investments and make recommendations to senior management
Desired Qualifications
  • Five or more years of relevant experience is preferred

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Geoffrey M. Glass appointed CEO July 22, 2025, drives growth.
  • Dr. Moncef Slaoui joins board January 8, 2025, boosts innovation.
  • Scientific Advisory Board formed May 15, 2025, guides ADC strategies.

What critics are saying

  • Lonza acquires Halo Life Science March 17, 2026, steals ADC share.
  • WuXi Biologics launches 10 ADC technologies Q1 2026, undercuts ThioBridge®.
  • FDA warning letter halts Bristol PA trials January 15, 2026.

What makes Abzena unique

  • ThioBridge® platform creates stable, effective ADCs for clients.
  • Composite Human Antibody™ reduces immunogenicity in biologics.
  • AbZelectPRO™ launches GS knockout CHO-K1 for afucosylated proteins.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Abzena who can refer or advise you

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth

Abzena
Apr 24th, 2025
Abzena's Customer Archetype Therapeutics to Present at AACR 2025 on Lung Cancer Drug Candidate Results

Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.